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Epstein–Barr virus (EBV) is a necessary cause of endemic Burkitt lymphoma (eBL), 
while the role of Plasmodium falciparum in eBL remains uncertain. This study aimed to 
generate new hypotheses on the interplay between both infections in the development 
of eBL by investigating the IgG and IgM profiles against several EBV and P. falciparum 
antigens. Serum samples collected in a childhood study in Malawi (2005–2006) from 442 
HIV-seronegative children (271 eBL cases and 171 controls) between 1.4 and 15 years 
old were tested by quantitative suspension array technology against a newly developed 
multiplex panel combining 4 EBV antigens [Z Epstein–Barr replication activator protein 
(ZEBRA), early antigen-diffuse component (EA-D), EBV nuclear antigen 1, and viral 
capsid antigen p18 subunit (VCA-p18)] and 15 P. falciparum antigens selected for their 
immunogenicity, role in malaria pathogenesis, and presence in different parasite stages. 
Principal component analyses, multivariate logistic models, and elastic-net regressions 
were used. As expected, elevated levels of EBV IgG (especially against the lytic antigens 
ZEBRA, EA-D, and VCA-p18) were strongly associated with eBL [high vs low tertile odds 
ratio (OR) = 8.67, 95% confidence interval (CI) = 4.81–15.64]. Higher IgG responses 
to the merozoite surface protein 3 were observed in children with eBL compared with 
controls (OR = 1.29, 95% CI = 1.02–1.64), showing an additive interaction with EBV 
IgGs (OR = 10.6, 95% CI = 5.1–22.2, P = 0.05). Using elastic-net regression models, 
eBL serological profile was further characterized by lower IgM levels against P. falciparum 
preerythrocytic-stage antigen CelTOS and EBV lytic antigen VCA-p18 compared with 
controls. In a secondary analysis, abdominal Burkitt lymphoma had lower IgM to EBV 
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and higher IgG to EA-D levels than cases with head involvement. Overall, this exploratory 
study confirmed the strong role of EBV in eBL and identified differential IgG and IgM 
patterns to erythrocytic vs preerythrocytic P. falciparum antigens that suggest a more 
persistent/chronic malaria exposure and a weaker IgM immune response in children with 
eBL compared with controls. Future studies should continue exploring how the malaria 
infection status and the immune response to P. falciparum interact with EBV infection in 
the development of eBL.
Keywords: endemic Burkitt lymphoma, epstein–Barr virus, Plasmodium falciparum, igg, igM, multiplex, children, 
africa
inTrODUcTiOn
Endemic Burkitt lymphoma (eBL), a highly aggressive B-cell 
non-Hodgkin lymphoma, is one of the most prevalent pediat-
ric cancers in areas of sub-Saharan Africa where Plasmodium 
falciparum transmission is high. Epstein–Barr virus (EBV) is 
found in almost all cases of eBL and is a necessary agent in the 
development of the tumor (1). eBL peaks at age 6–7  years, is 
more frequent in males, and the most common sites of presenta-
tion are jaws and abdomen. The occurrence of eBL is limited to 
P. falciparum holoendemic areas (2), and there is strong evidence 
that the parasite reactivates EBV both in vivo and in vitro (3, 4).
P. falciparum-specific antigens cause polyclonal B-cell activa-
tion and increase EBV-infected B-cell survival (5). The parasite 
deregulates the activation-induced deaminase enzyme that is 
associated with somatic hypermutation and class switch recom-
bination of immunoglobulin genes. This leads to DNA damage 
and increases the likelihood of c-myc translocations that, when 
happening in EBV-infected cells, leads to the development of 
lymphoma (6). In line with these observations, the International 
Agency for Research on Cancer categorized P. falciparum infec-
tion as a probable carcinogen (group 2A) in relation to the 
pathogenesis of eBL (7).
The intensity and timing of EBV and P. falciparum infections 
seem important features in eBL etiology. P. falciparum has been 
associated with earlier EBV acquisition and virus reactivation (8) 
and increases the frequency and duration of EBV events (9). Past 
and present exposure to infections in relation to eBL can be evalu-
ated using serological markers. Four prior case–control studies 
in Uganda, Malawi, Kenya and Ghana measured P. falciparum 
antibodies to evaluate associations between malaria infection 
history and eBL (10–13). Those studies assessed IgGs against 
(i) schizont extract by indirect immunofluorescence assay (10) or 
ELISA (11), (ii) histidin rich protein II, circumsporozoite surface 
protein (CSP-NANP6), SE36 subunit of serine repeat antigen-5 
protein, and merozoite surface protein 1 (MSP-142) by ELISA 
(13), and (iii) MSP-1, liver stage antigen 1 (LSA-1), and apical 
membrane antigen 1 (AMA-1) (12) by quantitative suspension 
array technology (qSAT). Serological analyses based on few 
antigens in Uganda and Malawi suggested that EBV and malaria 
act jointly on eBL, but their combined effect was not evaluated in 
Kenya and Ghana.
P. falciparum is a complex parasite with 5,000–6,000 predicted 
proteins and with a life cycle that comprises morphologically, 
sexual and antigenically distinct stages (preerythrocytic and 
erythrocytic) that are targeted by stage-specific immunity. Some 
antigenic epitopes of immunity are known, but there is not yet 
a validated set of proteins that can accurately indicate recent or 
past malaria exposure. A larger panel of antigens than that used 
in past case–control eBL studies is desirable to better character-
ize malaria serological patterns. Furthermore, previous studies 
on eBL only looked at IgG responses to both infections, but no 
measurement of IgM, as marker of primoinfection/current infec-
tion, was taken into account.
Here, we determined IgG and IgM serological signatures using 
a new multiplex panel combining 4 EBV and 15 P. falciparum 
antigens by qSAT in HIV-seronegative children from a cancer 
case–control study conducted in Malawi (11) to generate new 
hypotheses and get further insights into the interplay between 
EBV and P. falciparum infections in the development of eBL.
MaTerials anD MeThODs
study Participants
Anonymized serum samples from 609 Malawian children 
were tested. Samples had been collected as part of a childhood 
malignancy and blood-borne virus study conducted at the 
Queen Elizabeth Hospital in Blantyre, Malawi, between 2005 
and 2006 (11). Briefly, recruitment was performed in the pedi-
atric oncology ward. The mother or guardian of each child was 
invited to participate in the study; written informed consent 
was provided, and standardized questionnaires administered. 
eBL was clinically diagnosed and in 75% of cases was confirmed 
by histology. HIV seropositives and infants <1 year who might 
have maternal IgGs were excluded from the current analysis. 
Overall, 271 eBL cases and 171 controls between 1.4 and 
15 years old were analyzed (Figure 1). Controls included 159 
children diagnosed with Wilms tumor (n = 60), retinoblastoma 
(n = 11), rhabdomyosarcoma (n = 28), Kaposi sarcoma (n = 7), 
neuroblastoma (n =  13), hepatocellular carcinoma (n =  13), 
malignant teratoma (n = 3), bone tumor (n = 5), brain tumor 
(n = 3), ovarian tumor (n = 4), yolk sac tumor (n = 3), skin 
carcinoma (n = 2), salivary glands tumor (n = 1), metastasis 
(n =  1), and other soft tissue tumors (n =  5). Additional 12 
controls were children admitted to the oncology ward with a 
provisional diagnosis of cancer, who were subsequently found 
to have non-malignant conditions. All children diagnosed with 
hematological cancers (including leukemia, non-Burkitt lym-
phoma, and small round blue cell tumors), Hodgkin lymphoma 
FigUre 1 | Flowchart of endemic Burkitt lymphoma (eBL) cases and controls included in the study.
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or nasopharyngeal cancer were excluded from the control 
group because of possible diagnostic overlap and/or previously 
known strong associations with EBV. Among eBL cases, 113 
children presented with head tumors and 90 with abdominal 
tumors.
ethics statement
Ethical approval for the study was obtained from the Oxford 
Tropical Research Ethics Committee and the Malawian College 
of Medicine Research and Ethics Committee. The parent or 
guardian of each child provided written informed consent for 
their child to be included in the study in accordance with the 
Declaration of Helsinki.
laboratory Procedures
EBV GST-Fusion Proteins
Viral capsid antigen p18 subunit (VCA-p18), early antigen-diffuse 
component (EA-D), EBV nuclear antigen 1 (EBNA-1), and Z 
Epstein–Barr replication activator protein (ZEBRA) (12, 14) were 
expressed with pGEX vectors (Amersham) in Escherichia coli as 
double fusion proteins with N-terminal GST and a C-terminal 
peptide (tag). The proteins were affinity purified by incubation of 
glutathione displaying beads in bacterial lysate (15).
P. falciparum Recombinant Proteins
The antigens selected were based on their immunogenicity, 
their role in malaria pathogenesis and their presence in dif-
ferent parasite stages, some of them being vaccine candidates. 
Preerythrocytic antigens included the cell-traversal protein for 
ookinetes and sporozoites (CelTOS) (16), LSA-1 (17), sporo-
zoite surface protein 2 (SSP2) also known as thrombospondin-
related adhesion protein (18), and CSP (19), supplied by Protein 
Potential (USA). Blood-stage antigens included AMA-1 3D7 
(20), receptor-binding region F2 of the 175  kDa erythrocyte 
binding antigen (F2) (EBA-175) (21), duffy binding-like 
(DBL)-α domain of PfEMP-1 (22), DBL3X domain of VAR2CSA 
PfEMP-1 (23), merozoite surface protein 3 (MSP-3) 3D7 (24), 
Plasmodium thrombospondin-related apical merozoite protein 
(PTRAMP) (25), reticulocyte binding-like homolog proteins 2 
(Rh2) (26) and 5 (Rh5) (27), and cysteine-rich protective anti-
gen 2 (CyRPA2) (28), produced at ICGEB. AMA-1 FVO (29) and 
MSP-142 3D7 and FVO (30) were produced at WRAIR.
Measurement of Antibodies to EBV and  
P. falciparum Proteins by qSAT
A multiplex panel was established to quantify IgGs and IgMs 
against P. falciparum and EBV antigens using xMAP™ technol-
ogy (Luminex Corp., Austin, TX, USA) (31). Distribution of 
eBL cases and controls was balanced through plates. Briefly, 
1,000 microspheres were used per analyte and sample. EBV 
proteins were affinity purified on GSH-bearing beads, thus 
for EBV antigens, a fusion protein consisting of GST and tag 
without intervening viral antigen was coupled to beads to be 
used for background determination. P. falciparum proteins 
were covalently coupled directly to the beads and beads were 
blocked with BSA; thus for P. falciparum antigens, BSA coupled 
to the beads was used for background determination. Several 
plasma pools were used as positive controls in each plate: (i) a 
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P. falciparum hyperimmune Mozambican adult volunteers’ pool 
at 1/500 for IgG and 1/200 for IgM; (ii) an EBV immune Greek 
children pool (32) at 1/500 for IgG; and (iii) an EBV immune 
Malawi children pool (of samples with high IgM levels previ-
ously selected from the samples to be analyzed) at 1/200 for IgM. 
Several individual samples from malaria naïve European adults 
and non-EBV-exposed Greek children (32) were used as nega-
tive controls at 1/500 for IgG and 1/200 for IgM. Study samples 
were tested in duplicates at 1/500 and 1/20,000 for IgG and 1/200 
and 1/20,000 for IgM. Two wells per plate were assayed without 
plasma added as blank controls. To block antibodies directed 
against residual bacterial proteins and GST present on the beads 
loaded with EBV proteins, plasmas were preincubated at a 1:20 
dilution on a shaker at room temperature (RT) for 1 h in a serum 
preincubation buffer based on PBS, 1% BSA, 0.05% azide pH 7.4 
containing 2 g/L lysate from bacteria expressing GST alone (15). 
After sample preincubation, beads were incubated with plasma 
samples for 1 h. The plate was washed by pelleting microspheres 
using a magnet and resuspended with 0.05% Tween 20-PBS. 
One hundred microliters of biotinylated antihuman IgG or IgM 
(Sigma, Tres Cantos, Spain) at 1/2,500 and 1/1,000, respectively, 
in PBS 1% BSA 0.05% azide pH 7.4 (assay buffer), were applied 
and incubated for 45 min. The plate was washed as before, and 
100 µL of streptavidin-conjugated R-phycoerythrin (Invitrogen, 
Carlsbad, CA, USA) at 1/1,000 in assay buffer was added and 
incubated for 30 min. All incubations were done at RT with plate 
agitation (600  rpm) and protection from light. The plate was 
read using Luminex 200™ analyzer and Xponent software ver-
sion 3.1, and at least 50 microspheres per analyte were acquired 
per sample. Median fluorescence intensity (MFI) with blank 
fluorescence subtracted was exported, and arbitrary units (AU) 
concentration for each antigen was calculated by extrapolation 
from an IgG or IgM standard curve prepared by coupling beads 
to commercially available purified antihuman IgG and antihu-
man IgM specific to the F(ab′)2 region, and performing the assay 
using purified human IgG and human IgM as primary antibody.
Preprocessing of qSAT Data
Standard curves were fitted using four or five-parameter logistic 
equations depending on the best fit. The sample dilution closer to 
the EC50 of the curve was used to calculate the concentration (AU) 
as: EC50 (((Emin − Emax)/(MFI − Emax))^((1/Asym) − 1)^(1/Hill)), 
where EC50 is the half maximal effective concentration, Emin is the 
minimum response, Emax is the maximum response, Asym is the 
asymmetry factor, and Hill is the slope. Final concentrations were 
corrected by the dilution factor.
Seropositivity per antigen was defined as AU above the 
mean + 3 SDs of negative controls [non-malaria-exposed adults 
for P. falciparum and non-EBV-exposed children for EBV (32)]. 
EBV seropositivity was defined as positive IgGs against VCA-p18, 
EBNA-1 and EA-D, and positive IgM against VCA-p18 (33). 
P. falciparum seropositivity was defined as presence of antibodies 
to any of the parasite antigens.
statistical analysis
Raw Luminex data (AU) were log transformed and standardized 
to normalize and bring all of the variables into proportion with 
one another (with mean 0 and SD 1). All analyses were done 
primarily using continuous data to gain power and avoid loss 
of information (34). Correlations were examined by Pearson 
matrices. Associations between serological responses to each 
antigen and demographic factors were examined using linear 
regression models adjusted for age and sex, as appropriate. 
Principal component analysis (PCA) was performed with an 
orthogonal rotation on EBV and P. falciparum, separately, to 
obtain the structure of the data for each infection (Table S1 
in Supplementary Material). Two and five components were 
identified for EBV and P. falciparum, respectively. Based on 
PCA loading results, the two derived EBV components were 
labeled as “IgM EBV pattern” and “IgG EBV pattern.” Classical 
and multinomial logistic regression models were used to study 
the associations of antibodies, extracted principal components, 
and multiple seropositivity, with eBL. All models were adjusted 
for age (three categories: ≥1.41  <  3.75, ≥3.75  <  7.64, and 
≥7.64 years) and sex. Further adjustment was performed includ-
ing “IgG EBV pattern” (as continuous).
Elastic-net regression models were used to build an antibody 
response signature associated with eBL accounting for the high 
correlation and high dimensional scenario. Tuning elastic-net 
parameters (α and λ) were optimized using a 10-fold cross-
validation minimizing the deviance. The stability of the selected 
variables was assessed using bootstrap with replacement (number 
of iterations N = 500) with the pair of parameters (α, λ) optimized 
again at each bootstrap iteration. Variables were considered as 
highly important if their inclusion frequency was ≥70%.
Both multiplicative and additive interactions (relative excess 
risk due to interaction RERI and synergy index S) were examined. 
As this is a hypothesis-generating study, we did not adjust for 
multiple comparisons, and results were interpreted for internal 
coherence and biological plausibility. Analyses were performed 
using STATA13 (35) and R (36) using the glmnet (37), c060 (38), 
and NMF packages (39).
resUlTs
Demographic characteristics of study 
Participants
Table  1 shows demographic characteristics of participants. 
Controls were younger than cases [mean age (±SD): 6.3 (±3.7) 
and 7.8 (±2.9) years, respectively], with a proportion of children 
age of <4  years being much higher. Cases were more likely to 
be in the lower body mass index (BMI) tertile compared with 
the controls (51 vs 34%, respectively). The majority of cases and 
controls came from the South of Malawi (96 vs 87%, respectively). 
No differences were observed for other co-variables assessed.
serological characteristics of study 
Participants
Overall, 88% of children were seropositive for EBV: 77% of con-
trols and 96% of cases. Proportions by age group (≥1.41 < 3.75, 
≥3.75 <  7.64, and ≥7.64  years) were 79, 75, and 77% among 
controls, and 88, 96, and 95% among cases. There were no 
differences in EBV seropositivity by sex (86% males vs 90% 
TaBle 1 | Basic demographic characteristics of study participants.
controls
N (%)
cases
N (%)
P-het
N = 171 N = 271
age (years)
≥1.41 < 3.75 57 (33%) 16 (6%)
≥3.75 < 7.64 57 (34%) 124 (46%)
≥7.64 57 (33%) 131 (48%) <0.0001
Mean age (SD) 6.3 (3.7) 7.8 (2.9) <0.0001
Range 1.5–14.9 1.4–14.6
sex
Female 75 (44%) 110 (41%)
Male 99 (56%) 161 (59%) 0.50
Body mass index (kg/m2)
First tertile (<14.18) 54 (34%) 129 (51%)
Second tertile (≥14.18 ≤ 15.97) 53 (33%) 87 (34%)
Third tertile (≥15.97) 53 (33%) 37 (15%) <0.0001
country of residence
Malawi 162 (95%) 254 (94%)
Mozambique 9 (5%) 16 (6%) 0.77
region
Central 17 (10%) 9 (4%)
Northern 4 (2%) 1 (0%)
Southern 142 (87%) 244 (96%) 0.003
guardian at interview
Mother 135 (79%) 204 (76%)
Others 36 (21%) 66 (24%) 0.41
Numbers may not add to the total because of missing values.
N, number; P-het: P-heterogeneity.
The numbers in bold correspond to the associations that are statistically significant at 
the 5% level.
FigUre 2 | Pairwise correlations between logged antibody levels of both pathogens.
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and P. falciparum antigens, increasing age was associated with 
increasing antibody levels except for IgG VCA-p18 (Table S2 
in Supplementary Material). Males tended to have lower IgM 
responses to several malaria antigens. No pattern was observed 
in the serological response by geographical region or by chil-
dren’s BMI.
“igg eBV Pattern” and igg against  
P. falciparum MsP-3 antigen are 
associated with eBl
Strong correlations were observed between and within anti-
bodies for both pathogens, especially between IgMs. Overall 
correlations tended to be stronger in controls than in cases 
(Figure 2). As expected, IgG to specific EBV antigens and the 
PCA component “IgG EBV pattern” were strongly positively 
associated with eBL {adjusted odds ratio (OR) [95% confidence 
interval (CI) =  3.73 (2.75–5.08)]; Figure 3}. On the contrary, 
IgMs to EBV were not associated with eBL, except for IgMs 
against VCA-p18 that were negatively associated with eBL after 
adjusting for age and sex.
In relation to P. falciparum antigens, after controlling for age, 
sex, and “IgG EBV pattern,” positive associations were observed 
for IgG against MSP-3 (Figure 3). In contrast to EBV results, none 
of the five PCA components derived from P. falciparum serology 
were associated with eBL after controlling for age, sex, and “IgG 
EBV pattern” (data not shown).
iggs against Multiple P. falciparum 
erythrocytic antigens Weakly associated 
with eBl
Overall, joint presence of antibodies to multiple P. falciparum 
antigens was not associated with eBL after adjustment for age, 
sex, and “IgG EBV pattern” (Table  2). When antibodies were 
females). For P. falciparum, 99% children were IgG seroposi-
tive (99% cases and 98% controls) and 84% IgM seropositive 
(85% cases and 82% controls). Among controls, for most EBV 
TaBle 2 | ORs of endemic Burkitt lymphoma for the burden of IgGs to Plasmodium falciparum antigens.
risk factors controls N (%) cases N (%) Ora (95% ci) P-trend Orb (95% ci) P-trend
all P. falciparum antigens
Lowerc 58 (34) 42 (15) Ref Ref
Medium 58 (34) 125 (46) 2.44 (1.42–4.21) 1.72 (0.94–3.17)
Higher 55 (32) 104 (38) 1.89 (1.08–3.29) 0.06 1.39 (0.75–2.58) 0.40
1 U increase 1.04 (1.01–1.07) 0.005 1.02 (0.99–1.05) 0.18
Preerythrocytic antigens
Lowerc 76 (44) 99 (37) Ref Ref
Medium 41 (24) 76 (28) 1.26 (0.75–2.12) 1.00 (0.56–1.81)
Higher 54 (32) 96 (35) 1.08 (0.67–1.76) 0.72 0.81 (0.47–1.41) 0.47
1 U increase 1.03 (0.93–1.13) 0.58 0.97 (0.87–1.08) 0.56
erythrocytic antigens
Lowerc 60 (35) 36 (13) ref Ref
Medium 59 (35) 121 (45) 2.71 (1.55–4.74) 1.87 (1.00–3.48)
Higher 52 (30) 114 (42) 2.60 (1.48–4.60) 0.003 1.85 (0.98–3.49) 0.08
1 U increase 1.07 (1.03–1.11) 0.001 1.04 (1.00–1.09) 0.05
Ref, reference; OR, odds ratio; CI, confidence interval.
aAdjusted for age (three categories) and sex.
bAdjusted for age, sex, and the principal component analysis component “IgG Epstein–Barr virus pattern.”
cThe burden was calculated creating a score by adding tertiles values of the log-transformed data (coded as 1, 2, and 3) for each antigen and dividing the score into three groups 
based on the control distribution. Preerythrocytic antigens: CelTOS, SSP2, CSP and LSA-1.
The numbers in bold correspond to the associations that are statistically significant at the 5% level.
FigUre 3 | Odds ratios (ORs) for endemic Burkitt lymphoma in relation to IgG and IgM levels against single Epstein–Barr virus (EBV) and Plasmodium falciparum 
antigens and against EBV PCA components.
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further grouped following parasite stages, a positive associa-
tion was observed for the joint presence of IgGs to erythrocytic 
antigens [OR (95% CI) for seropositivity to third tertiles = 1.04 
(1.00–1.09)] but not for IgGs to preerythrocytic antigens. No 
associations were observed for joint presence of multiple IgMs 
(data not shown).
FigUre 4 | Selecting important Epstein–Barr virus (EBV) and Plasmodium falciparum antigen-specific antibodies for endemic Burkitt lymphoma using elastic-net 
penalized regression models.
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antibody response signature for eBl
The antibody response signature for eBL included antibodies to 7 
antigens out of the 38 examined (Figure 4). Highest eBL positive 
ORs were observed for increasing IgGs against the three EBV lytic 
antigens EA-D, and VCA-p18 (OR = 1.53 and 1.29, respectively), 
and to a lesser extent for increasing IgG to the latent antigen 
EBNA-1 and the lytic antigen ZEBRA (OR = 1.13 for both anti-
gens). Regarding the IgM EBV repertoire, OR of eBL decreased 
with increasing IgM to VCA-p18 (OR = 0.97). In relation to Igs to 
P. falciparum, children with eBL were more likely to have higher 
IgG against MSP-3 (OR = 1.18) and lower IgM against CelTOS 
(OR = 0.94).
additive interaction between iggs against 
eBV and MsP-3
An additive effect of the “IgG EBV pattern” and IgG seropositiv-
ity to MSP-3 was observed that significantly increased the OR 
of eBL beyond the associated with each factor independently 
[OR (95% CI) for high “IgG EBV pattern” and IgG seropositivity 
to MSP-3 compared with low/seronegativity = 10.6 (5.1–22.2)]. 
However, this interaction reached borderline statistical sig-
nificance (P =  0.05) (Figure  5). No other interactions were 
observed.
association between antibody responses 
and Tumor location
Cases with abdominal tumors were older than cases with jaw 
tumors [mean (SD) age: 8.9 (0.3) vs 6.9 (0.2) years, respectively; 
P < 0.001] and more likely to be female (47 vs 32%, P = 0.03). The 
association between tumor location and the assessed antibodies 
as well as PCA compounds was examined for both infections 
(Figure 6). Compared with controls, OR for abdominal tumors 
decreased with increasing IgM against EBV, whereas no differ-
ence was observed in children with head tumors (all P-values for 
heterogeneity between tumor location <0.05). Regarding IgGs to 
EBV antigens, only IgG to EA-D was positively associated with 
higher OR for abdominal tumors compared with head tumors 
(P  =  0.05). No associations were observed for antibodies to 
P. falciparum and tumor location (data not shown).
DiscUssiOn
This study aimed to give further insight into the combined effect 
of EBV and P. falciparum in the development of eBL by analyzing 
IgG and IgM patterns to 4 EBV and 15 P. falciparum antigens 
(10 never used before, including 3 preerythrocytic) in Malawian 
children from a cancer case–control study (11). As expected, 
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our data support a strong role of EBV in eBL, and a weak effect 
of malaria, but suggest that both infections might act jointly on 
eBL, as shown by the additive interaction between elevated IgGs 
against EBV and MSP-3. In agreement with this observation, two 
recent studies have reported that the key determinants of EBV 
primary infection kinetics in children are the degree of malaria 
exposure and maternal antibody decay (9, 40).
The study population showed a high EBV seroconversion at a 
young age (>3/4 of the controls age ≤3.8 years), contrasting with 
recent estimates from Crete where only 50% of children at age 
4 years had seroconverted (32). As expected, elevated EBV IgG 
levels were strongly positively associated with eBL (10–12, 41), 
whereas high anti-VCA-p18 IgM responses were negatively asso-
ciated with eBL. In particular, IgG levels to the three EBV lytic 
antigens (EA-D, marker of active infection and viral reactivation, 
ZEBRA involved in the switch from latent to lytic stage, and VCA-
p18) were higher compared with IgG against EBNA-1 (latency 
marker). High IgM levels against VCA-p18 usually indicate 
recent primary EBV infection, although it may persist for months 
or might reappear in EBV reactivation. The negative association 
of high IgM anti-VCA-p18 levels with eBL suggests that newly 
EBV-infected children might be at lesser risk of eBL compared 
with children exposed for a longer time, or might indicate that in 
a malaria endemic region the long-term persistence of anti-VCA 
IgM responses may be associated with a better control of EBV 
infection (40).
In contrast to the strong EBV association, we only observed 
weak associations for few of the 15 antibodies measured against 
P. falciparum antigens, which is difficult to interpret as serological 
understanding of P. falciparum exposure and acquired immunity 
are not yet fully elucidated (42). However, the observed differ-
ences are probably related to the diverse immunogenicities of 
these antigens. The strongest and most consistent association 
was found for IgG against MSP-3, a highly immunogenic antigen 
involved in merozoite binding to human erythrocytes (43). 
Anti-MSP-3 IgG responses have been associated with protection 
against malaria in some sero-epidemiological studies (44, 45), but 
in others just showed to be exposure markers (46, 47). Higher bur-
den of IgGs against multiple merozoite proteins was observed in 
eBL patients compared with controls suggesting that a persistent/
chronic malaria exposure might enhance EBV infection as well 
as reactivation. To deal with the issue of assessing associations 
for correlated EBV and P. falciparum antigen-specific antibodies, 
we used elastic-net regression models to select a subset of the 
most important antibodies for eBL, mutually adjusted for each 
other. While getting inference testing on the selected antigens for 
elastic-net is still an open statistical question, the results allow 
us to generate some new hypotheses. The higher IgM responses 
to the liver-stage antigen CelTOS were inversely associated with 
eBL, suggesting that newly malaria-infected children might be at 
lesser risk of eBL compared with children exposed for a longer 
time. Alternatively, the long-term persistence of anti-CelTOS 
IgM responses may be associated with a better control of malaria 
infection. CelTOS-specific cellular immunity has been detected 
among protected subjects in a controlled human malaria infec-
tion study (48), and antibodies to CelTOS have been shown to 
correlate with naturally acquired clinical immunity (49). Also, a 
recent study reports that anti-CelTOS responses prevent hepato-
cyte infection by sporozoites (50).
As secondary analysis, we observed that lower ”EBV IgM pat-
tern” and higher IgG responses to EA-D occurred in children with 
abdominal tumor presentation compared with head location. 
This differs to results from a previous study (N = 14 jaw and 16 
abdominal tumors) where higher anti-ZEBRA but not anti-EA-D 
IgG levels were associated with abdominal tumors (12). Here, IgG 
levels to EA-D highly correlated with ZEBRA IgG, particularly 
among cases, and consequently both IgG responses to ZEBRA and 
EA-D were elevated in children with abdominal vs head tumors, 
but results were only statistically significant for EA-D. We also 
observed that children with abdominal tumors were more likely 
to have lower EBV IgMs, suggesting that abdominal compared 
with jaw tumors may arise more frequently in long-standing EBV 
infections. In turn, this longer EBV exposure could explain the 
observed age difference between distinct clinical presentations, 
with abdominal eBL occurring more often among older children.
Our study has some limitations. First, results are based on 
case–control data, so temporality of infections and causality of 
associations cannot be determined. Thus, the observed associa-
tions with the two infections could be due to reverse causality since 
changes in antibody levels could be consequence of eBL disease. 
The use of hospital oncologic controls might be another limita-
tion. Although we excluded all children diagnosed with hemato-
logical cancers, Hodgkin lymphoma or nasopharyngeal tumors, 
FigUre 5 | Additive interactions for endemic Burkitt lymphoma between 
“Epstein–Barr virus (EBV) IgG pattern” and IgG to merozoite surface protein 3 
antigen.
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FigUre 6 | Adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for endemic Burkitt lymphoma in relation to IgG and IgM levels against Epstein–Barr virus 
(EBV) antigens by tumor location.
to avoid possible diagnostic overlap with eBL, and to exclude 
those with known associations with EBV, we cannot discard that 
some of these other conditions might be affecting the antibody 
responses to EBV and P. falciparum antigens. Misclassification in 
cases and tumor location might have occurred, as 25% of cases 
and controls did not have a histological verification of diagnosis; 
children might have had metastasis at hospital arrival, making 
the classification difficult. In addition, the understanding of the 
sero-epidemiology of P. falciparum is at an early stage, making 
the interpretation of the findings challenging. It would have 
been informative to examine the serological responses in rela-
tion to EBV and parasite densities, but this information was not 
available. However, the elevated levels of IgG to EA-D reflect 
an increased production of EBV DNA and hence might be a 
surrogate of EBV-viral load. Finally, multiple associations were 
evaluated and chance in some of them cannot be excluded, thus 
the weak associations observed for some P. falciparum antigens 
with eBL and the additive interaction of MSP-3 with EBV must 
be taken with caution. Nevertheless, the confirmation of previous 
findings and the internal consistency of results make us confident 
that the findings are robust.
In conclusion, we found a strong association between EBV and 
eBL, and identified new associations between specific antibodies 
to P. falciparum, EBV, and eBL. Multiple P. falciparum antibody 
responses and differential effects by liver- vs blood-stage infec-
tions might reflect a complex mechanism whereby the parasite 
modulates the association between EBV and eBL. Longitudinal 
studies with more immunological and molecular data on EBV 
and P. falciparum infections are needed to better understand the 
combined mechanism of the two infections in eBL etiology. Future 
studies on eBL should collect information on tumor location 
since the infections might act differently by tumor presentation. 
The development of vaccines against these two infections would 
be crucial to protect African children from eBL.
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